News

Featured News

  • 2023 |
  • 2022 |
  • 2021 |
  • 2020 |
  • 2019 |
  • 2018 |
  • 2017 |
  • View All
  • Press Release | February 2, 2023

    Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors

    Read More

    Press Release | February 1, 2023

    Dr. Joseph E. Eid, Who Led Merck’s Pioneering Clinical Development of KEYTRUDA®, joins Dragonfly Therapeutics as President of R&D

    Read More

    Press Release | January 31, 2023

    Carisma Therapeutics Appoints Leading Solid Tumor Immunotherapy Expert Padmanee Sharma, MD, PhD to Scientific Advisory Board

    Read More

    Press Release | January 27, 2023

    Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

    Read More

    Press Release | January 22, 2023

    Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients with Idiopathic Pulmonary Fibrosis

    Read More

    Press Release | January 18, 2023

    Freenome Partners with Geisinger for the Sanderson Study

    Read More

    Education | January 12, 2023

    Agent Capital’s Associate, Jonathan Ark’s PhD Work Published in Cell

    Read More

    Press Release | January 11, 2023

    Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD)

    Read More

    Press Release | January 9, 2023

    Orchard Therapeutics Highlights Recent Progress Across HSC Gene Therapy Portfolio and Outlines Key 2023 Milestones

    Read More

    Press Release | January 6, 2023

    Dragonfly Therapeutics Announces Sixth Dragonfly TriNKET Opt-in by Bristol Myers Squibb

    Read More

    Press Release | January 6, 2023

    Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Company’s Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, its Lead Allogeneic CAR T Clinical Candidate

    Read More

    Press Release | January 5, 2023

    Palvella Therapeutics Announces Series D Financing of Up to $37.7 Million to Accelerate Late-Stage Development and Support Commercialization of Novel Therapies for Serious, Rare Genetic Skin Diseases

    Read More

    Press Release | January 5, 2023

    Orchard Therapeutics Announces U.S. FDA Clearance of IND Application for OTL-203 in MPS-IH

    Read More

    Press Release | January 5, 2023

    Metagenomi Closes Oversubscribed Series B Financing Totaling $275M to Advance Lead Therapeutic Programs into Clinical Development and Grow Genetic Medicines Pipeline

    Read More

    News | January 4, 2023

    Top Life Sciences Startups to Watch in 2023

    Read More

    Press Release | January 4, 2023

    Immunitas Therapeutics Announces First Patient Dosed in Phase 1/2a Study of IMT-009

    Read More

    News | January 3, 2023

    Viewpoint: Expanding TRIPS waiver is bad for innovation

    Read More